Maureen Hillenmeyer, Hexagon Bio CEO
September 22, 2021 10:51 AM EDTUpdated 01:44 PM
Financing

Hexa­gon Bio rais­es $61M to con­tin­ue ef­forts to turn fun­gi in­to drugs

Paul Schloesser

Associate Editor

A year af­ter rais­ing a $47 mil­lion launch round, the fun­gi-lov­ing drug hunters at Hexa­gon Bio have more than dou­bled their cof­fers.

Hexa­gon …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Mer­ck pays $30M to buy ‘chameleon’ ap­proach to dead­ly brain can­cers

Eye drop mak­er to merge with a reti­nal gene ther­a­py start­up from Spark co-founder

UK’s price watch­dog says Lil­ly’s Alzheimer’s drug is too cost­ly for broad up­take

Cor­rect­ed: Sang­amo to seek ac­cel­er­at­ed ap­proval for Fab­ry gene ther­a­py, claims it won't need con­fir­ma­to­ry study

Am­gen preps to launch Eylea biosim­i­lar years ear­ly af­ter Re­gen­eron los­es ap­peal

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times